These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 37769625)

  • 21. Tertiary lymphoid structures favor outcome in resected esophageal squamous cell carcinoma.
    Li R; Huang X; Yang W; Wang J; Liang Y; Zhang T; Mao Q; Xia W; Xu L; Xu X; Dong G; Jiang F
    J Pathol Clin Res; 2022 Sep; 8(5):422-435. PubMed ID: 35711130
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tertiary lymphoid structures as potential biomarkers for cancer prediction and prognosis.
    Zhang X; Yao J; Xie M; Liang Y; Lin X; Song J; Bao X; Ma X; Wang Y; Zhang Y; Liu Y; Han W; Pan L; Xue X
    Int Immunopharmacol; 2024 Oct; 140():112790. PubMed ID: 39088920
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tertiary lymphoid structures in tongue cancer: Association with clinicopathological parameters, preoperative S-1 chemotherapy response, and prognosis.
    Seki M; Sano T; Saito E; Ogawa M; Yokoo S; Oyama T
    J Oral Pathol Med; 2024 Feb; 53(2):124-132. PubMed ID: 38183312
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tertiary lymphoid structures: new immunotherapy biomarker.
    Yang F; Yang J; Wu M; Chen C; Chu X
    Front Immunol; 2024; 15():1394505. PubMed ID: 39026662
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Insights into tertiary lymphoid structures in the solid tumor microenvironment: anti-tumor mechanism, functional regulation, and immunotherapeutic strategies.
    Zhao H; Wang H; Zhou Q; Ren X
    Cancer Biol Med; 2021 Sep; 18(4):981-91. PubMed ID: 34553849
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Distribution and density of tertiary lymphoid structures predict clinical outcome in intrahepatic cholangiocarcinoma.
    Ding GY; Ma JQ; Yun JP; Chen X; Ling Y; Zhang S; Shi JY; Chang YQ; Ji Y; Wang XY; Tan WM; Yuan KF; Yan B; Zhang XM; Liang F; Zhou J; Fan J; Zeng Y; Cai MY; Gao Q
    J Hepatol; 2022 Mar; 76(3):608-618. PubMed ID: 34793865
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tertiary lymphoid structure signatures are associated with survival and immunotherapy response in muscle-invasive bladder cancer.
    Zhou L; Xu B; Liu Y; Wang Z
    Oncoimmunology; 2021 May; 10(1):1915574. PubMed ID: 34104539
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The roles of tertiary lymphoid structures in chronic diseases.
    Sato Y; Silina K; van den Broek M; Hirahara K; Yanagita M
    Nat Rev Nephrol; 2023 Aug; 19(8):525-537. PubMed ID: 37046081
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tertiary Lymphoid Structures in Cancer: The Double-Edged Sword Role in Antitumor Immunity and Potential Therapeutic Induction Strategies.
    Kang W; Feng Z; Luo J; He Z; Liu J; Wu J; Rong P
    Front Immunol; 2021; 12():689270. PubMed ID: 34394083
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tertiary lymphoid structures in gynecological cancers: prognostic role, methods for evaluating, antitumor immunity, and induction for therapy.
    Zhang K; Xie X; Zheng SL; Deng YR; Liao D; Yan HC; Kang X; Jiang HP; Guo SQ
    Front Oncol; 2023; 13():1276907. PubMed ID: 38023214
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tertiary lymphoid structures in cancer.
    Schumacher TN; Thommen DS
    Science; 2022 Jan; 375(6576):eabf9419. PubMed ID: 34990248
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Single-cell sequencing reveals the heterogeneity of B cells and tertiary lymphoid structures in muscle-invasive bladder cancer.
    Yuan H; Mao X; Yan Y; Huang R; Zhang Q; Zeng Y; Bao M; Dai Y; Fang B; Mi J; Xie Y; Wang X; Zhang H; Mo Z; Yang R
    J Transl Med; 2024 Jan; 22(1):48. PubMed ID: 38216927
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intratumoral tertiary lymphoid structures promote patient survival and immunotherapy response in head neck squamous cell carcinoma.
    Liu Z; Meng X; Tang X; Zou W; He Y
    Cancer Immunol Immunother; 2023 Jun; 72(6):1505-1521. PubMed ID: 36481914
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tertiary lymphoid structures in pulmonary metastases of microsatellite stable colorectal cancer.
    Karjula T; Niskakangas A; Mustonen O; Puro I; Elomaa H; Ahtiainen M; Kuopio T; Mecklin JP; Seppälä TT; Wirta EV; Sihvo E; Yannopoulos F; Helminen O; Väyrynen JP
    Virchows Arch; 2023 Jul; 483(1):21-32. PubMed ID: 37337034
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tertiary lymphoid structures in breast ductal carcinoma in situ correlate with adverse pathological parameters.
    Zeng L; Koh VCY; Chen XY; Tan PH
    Histopathology; 2023 Apr; 82(5):779-788. PubMed ID: 36635954
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic impact of tertiary lymphoid structures in breast cancer prognosis: a systematic review and meta-analysis.
    Zhang NN; Qu FJ; Liu H; Li ZJ; Zhang YC; Han X; Zhu ZY; Lv Y
    Cancer Cell Int; 2021 Oct; 21(1):536. PubMed ID: 34654433
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The roles of tertiary lymphoid structures in genitourinary cancers: molecular mechanisms, therapeutic strategies, and clinical applications.
    Yang J; Xiong X; Zheng W; Xu H; Liao X; Wei Q; Yang L
    Int J Surg; 2024 Aug; 110(8):5007-5021. PubMed ID: 38978471
    [TBL] [Abstract][Full Text] [Related]  

  • 38. B cells and tertiary lymphoid structures are associated with survival in papillary thyroid cancer.
    Li YY; Li SJ; Liu MC; Chen Z; Li L; Shen F; Liu QZ; Xu B; Lian ZX
    J Endocrinol Invest; 2023 Nov; 46(11):2247-2256. PubMed ID: 37004696
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tailoring biomaterials for monitoring and evoking tertiary lymphoid structures.
    Li H; Lin WP; Zhang ZN; Sun ZJ
    Acta Biomater; 2023 Dec; 172():1-15. PubMed ID: 37739247
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Density and maturity of peritumoral tertiary lymphoid structures in oesophageal squamous cell carcinoma predicts patient survival and response to immune checkpoint inhibitors.
    Hayashi Y; Makino T; Sato E; Ohshima K; Nogi Y; Kanemura T; Honma K; Yamashita K; Saito T; Tanaka K; Yamamoto K; Takahashi T; Kurokawa Y; Miyata H; Nakajima K; Wada H; Morii E; Eguchi H; Doki Y
    Br J Cancer; 2023 Jun; 128(12):2175-2185. PubMed ID: 37016103
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.